Skip to main content
NCBI home page
The Brown Journal of Hospital Medicine logoLink to The Brown Journal of Hospital Medicine
. 2022 Nov 1;2(1):39745. doi: 10.56305/001c.39745

Antibiotic-Associated Diarrhea Beyond C. Difficile: A Scoping Review

Vijairam Selvaraj 1, Mohd Amer Alsamman 2
PMCID: PMC11878822  PMID: 40046540

Abstract

A common complication of antibiotic use is the development of diarrheal illness. The pathogenesis of antibiotic associated diarrhea (AAD) may be mediated through alteration of intestinal microbiota, overgrowth of opportunistic pathogens, and direct drug toxicity on the gut. Alterations in the intestinal microbiota result in metabolic imbalances, loss of colonization resistance and in turn allow proliferation of opportunistic pathogens. Currently fewer than 33% of AAD cases can be attributable to Clostridioides difficile leaving a large number of cases undiagnosed and poorly treated. Although the pathogenesis of Clostridioides difficile infection (CDI) has been well documented, the role of other putative microbial etiologies (Clostridium perfringens, Staphylococcus aureus, Klebsiella oxytoca, Candida species) and their pathogenic mechanisms in AAD has been unclear. This review provides a comprehensive and systematic approach to the existing data on AAD and includes concise descriptions of the pathogenesis of CDI and non-CDI AAD in the form of figures.

Keywords: AAD, Antibiotic associated diarrhea, Cdifficile, Cdifficile infection, Diarrhea, clostridium difficile, staphylococcus aureus

BACKGROUND

Most antibiotics lead to important alterations of intestinal microbiota, often resulting in diarrhea. Antibiotic associated diarrhea (AAD) is defined as passage of three or more unformed stools per day beginning anywhere from within a few hours up to 8 weeks after starting antibiotic therapy.1,2 The frequency of AAD has been reported to occur in 5-35% persons exposed to antimicrobials and varies upon the class of antibiotics received, health of the host and exposure to pathogens.3 AAD may range from mild, self-limiting illness to fulminant, pseudomembranous colitis that can be life threatening.4,5

The first cases of antibiotic-associated colitis were described in 1950s and 1960s soon after the introduction of antimicrobial drugs with activity against Staphylococcus aureus being identified as a pathogen in some cases. Before the identification of Clostridioides difficile infection (CDI), oral vancomycin was shown to effectively treat staphylococcal enterocolitis.6 In the early 1970s an outbreak of clindamycin-associated pseudomembranous colitis led to the modern era of CDI.7,8 Currently, studies estimate that there may be up to nearly half a million CDI cases every year, making it the most common bacterial cause of diarrhea in the United States.9 In spite of this number, a large proportion of AAD cases seem to be due to other causes. Studies have looked at some of the other causes that may be responsible for non-CDI AAD including other putative microbial etiologies.10,11

The likely pathogenesis of AAD includes alteration of intestinal microbiota, direct drug toxicity on the gut and development of a superinfection by a pathogenic microbe. The normal intestinal microbiota importantly contributes to intestinal homeostasis and colonization resistance by pathologic microflora by production of antimicrobial metabolites, utilization of micronutrients and space, and modulation of the gut immune system.12 Administration of antibiotics causes changes in the fecal flora and creates gaps in ecological niches that allow proliferation of opportunistic microbes. Although the role of C. difficile in the pathogenesis of AAD has been well studied, there are considerable gaps in our understanding of the pathogenesis of non-CDI AAD due to putative microbial etiologies including C. perfringens, S. aureus, K. oxytoca, and Candida species. Identifying the etiology and understanding the pathogenesis of AAD will help in improving healthcare and in reducing the economic burden.

The review will also focus on the alteration of intestinal microflora and will provide a stronger basis for the use of non-pharmacologic therapies such as synbiotics (combination of prebiotics and probiotics that benefit the host by inhibiting the growth of pathogenic bacteria and enhancing the growth of beneficial organisms) as an effective therapeutic and preventive strategy. The overall objective is to review the existing data and acquire a better understanding of the various pathophysiologic mechanisms of AAD. Specific aims are: (1) to examine the roles of various microbial organisms in etiology of AAD (2) to understand the pathogenesis of C. difficile as well as non-C. difficile AAD.

METHODS

A comprehensive literature search was undertaken in Medline via Ovid and Pubmed databases as of July 31, 2022, using the key words: Clostridioides difficile, difficile, diarrhea, antibiotic associated diarrhea, AAD, colitis, enteritis, pseudomembranous colitis, CDI, CDAD, Staphylococcus, Klebsiella, Candida and Clostridium perfringens. For each organism, studies evaluating their role in pathogenesis of AAD were evaluated. Initially, studies were eligible if they referred to diarrheal illness or enteric infection by any organism following use of antibiotics. They were then narrowed down to any aspect of pathogenesis relating to enteric infection by specific organisms such as Staphylococcus, Klebsiella, Candida, C. difficile and C. perfringens. The list was further narrowed after performing a manual search of the full text for the relevant primary studies to identify their relevance and to extract any additional data.

An example of one such search strategy employed for Candida and antibiotic associated diarrhea in PubMed was (“Candida” [MeSH terms] OR “Candida”[All fields]) AND (“antibiotic associated diarrhea” [MeSH terms] OR “AAD” [MeSH terms] OR (“antibiotic associated” [All fields] AND (“diarrhea”[All Fields] OR “diarrhoea”[All Fields] OR “colitis”[All Fields”] OR “enteritis” [All Fields] OR “enterocolitis”[All Fields])) OR “antibiotic associated diarrhea”[All fields] OR “AAD”[All Fields] OR ((“anti-bacterial agents[Adverse effects] OR antibiotic-associated[All Fields] OR”AAD”[All Fields]) AND (“diarrhea”[All Fields] OR “diarrhoea”[All Fields] OR “diarrhea”[Chemically induced]).

We reviewed published original articles, case reports, case series and abstracts in peer reviewed journals. Bibliographies from review articles were also scanned. No language and date restrictions were applied. Both human as well as animal studies were initially screened. Data synthesized was used to construct evidence tables, flow charts and figures to illustrate the different pathophysiologic mechanisms involved. Additional details on salient features of studies and potential biases were mentioned in the comments section of the table. Data was evaluated for inclusion and extracted from eligible studies independently by two authors.

RESULTS & DISCUSSION

The human intestinal microbiota plays an important role in the maintenance of host health through formation of short chain fatty acids and secondary bile acids, modulation of the immune system and development of colonization resistance. Colonization resistance describes the ability of the intestinal microbiota to resist invasion by exogenous microorganisms by means of host factors such as production of inhibitory substances, attachment interference, nutrient depletion, along with the production of toxic antagonistic compounds.13 Numerous adverse effects to antibiotics have been associated with changes in the intestinal microbiota including diarrhea, acquisition of CDI, emergence of antibiotic resistant strains of enteric pathogens, and a decline in colonization resistance. Figure 1 provides an overview of the pathogenesis of AAD.

Figure 1. Pathogenesis of AAD.

Figure 1.

Open in a new tab

Alterations in metabolic functions of normal intestinal flora

Carbohydrates reaching the colon such as resistant starch, dietary fiber, unabsorbed sugars, and oligosaccharides undergo anaerobic fermentation in a progressive manner from proximal to distal colon. This fermentation leads to the production of short chain fatty acids (SCFAs) such as acetate, butyrate, proprionate, as well as lactic acid and gases. Altered intestinal microbiota from antibiotic exposure results in diminished absorption of carbohydrates by reducing the fermentation of SCFAs. The presence of unfermented carbohydrates overwhelms the colon mucosa and retains fluid in colonic lumen resulting in osmotic diarrhea.14 In-vitro studies have shown that even healthy subjects lose their ability to metabolize carbohydrates in the presence of antibiotics.15 Diminished production of SCFA with alteration of gut microbiota also deprives the colonic mucosa of an efficient energy source.16 Reduced concentrations of SCFA are found in healthy subjects as well as patients taking antibiotics with activity against anaerobic bacteria.17

Primary bile salts synthesized by the liver are mainly composed of cholate and chenodeoxycholate, conjugated with either taurine or glycine. The intestinal microbiota possesses bile salt hydrolases that play an important role by removing the conjugates from the primary bile salts. Deconjugated salts are dehydroxylated by 7α dehydroxylating bacteria in the large bowel to deoxycholic acid and lithocholic acid and are simultaneously precipitated from solution. Reduced amounts of 7α dehydroxylating bacteria following antibiotic exposure may result in elevated levels of chenodeoxycholic acid, resulting in secretory diarrhea.18

Microbial Causes of AAD

In Table 1, the role of putative microbial etiologies in AAD are listed. Administration of antibiotics causes alteration of intestinal microbiota with loss of colonization resistance. This results in overgrowth of organisms from exogenous origin or from other regions of the gut that may alter gut function. Antibiotic resistant endogenous organisms may overgrow with their selective advantage during antimicrobial therapy and occasionally resistant pathogens may be encouraged to grow when kept normally in small numbers by normal flora.

Table 1. Role of putative microbial organisms in AAD.

Pathogenetic mechanism Disease caused Animal model Comments
C. difficile Toxin A, B & binary toxin Diarrhea
Colitis
Enteritis 105 		Yes C. difficile has been proven to cause AAD. C. difficile AAD is reported to be 4 and 60 times more common than C. perfringens or S. aureus, respectively.19
K. oxytoca Cytotoxin mediated Antibiotic associated hemorrhagic colitis (AAHC) Yes Distinct right sided colitis is reported in patients with C. difficile negative AAHC. AAHC is considered a distinct entity by itself & K. oxytoca is considered in patients with C. difficile negative bloody diarrhea.107
C. perfringens Enterotoxin mediated Diarrhea
Colitis		 N/A C. perfringens enterotoxin has been detected in studies along with C. difficile toxin and may act alone or in synergy. Nosocomial C. perfringens is commonly isolated in elderly inpatients after antibacterial therapy.
S. aureus Enterotoxin & leucotoxin mediated Diarrhea
Enterocolitis		 N/A Studies reported distinct clinical features in patients where S. aureus enterotoxin was isolated. MRSA was predominantly isolated; valid etiologic role present in C. difficile negative enteritis & enterocolitis, especially in patients with predominant S. aureus in stools.
Candida spp. Immuno-suppression; ↓lactase activity & ↑secretion of water, Na+ & K+ in vitro Diarrhea
Colitis		 N/A No studies till date that have conclusively proven role of Candida in AAD. Diarrhea resulting from Candida overgrowth may be considered in elderly hospitalized patients receiving antibiotics.
Open in a new tab

C. difficile is the most identified cause of AAD. Clinical manifestations in CDI range from short-term colonization, acute diarrhea, fulminant diarrhea, which may be associated with pseudomembranous colitis and leukocytosis and may lead to death, and recurrent CDI (rCDI).9 The severity of illness may depend on risk factors such as age, host immune status, number of prior hospitalizations and presence of co-morbidities. Major risk factors include advanced age, hospitalization, and exposure to antibiotics. Important pathophysiologic alterations seen in CDI are highlighted in Figure 2. An exposure to vegetative cells and/or spores of C. difficile, antibiotic alteration of intestinal microbiota and exposure to bile salts which convert spores to vegetative cells can lead to the propagation of C. difficile in the gut.20 Other factors involved in CDI pathogenesis include proteolytic enzymes released from the organism such as cysteine protease Cwp84 and bacterial adhesins such as flagellin Fli-C, flagellar cap protein Fli-D and Cwp 66, fibronectin binding protein Fbp 68 heat shock protein GroEL, and surface (S) layer proteins such as P36 and P47.21–29

Figure 2. Pathogenesis of Clostridioides difficile Infection (CDI).

Figure 2.

Open in a new tab

The two main toxins of C. difficile, toxins A and B play a critical role in the pathophysiology of CDI. Both are enterotoxic and cytotoxic; however, traditionally toxin A is named “enterotoxin A” and toxin B is named “cytotoxin B”. Toxins A and B share 63% of common amino acid sequence homology and play a significant role in the mucosal inflammation and injury seen in CDI.30 Strains of C. difficile may also produce a binary toxin (or Clostridioides difficile transferase) first described by Popoff et al.31 This toxin consists of a binding component, an enzymatic component and also demonstrates actin specific ADP ribosyl transferase activity that causes cytoskeletal re-organization and cell death.32 It is frequently seen in the hypervirulent North American Phage type 1 (NAP1) (also Ribosome 027) strain of C. difficile, which was found to produce 16 times more toxin A and B than other strains. The BI/NAP1/027 strain is usually resistant to fluoroquinolones, exhibits intensive spore production, and is responsible for the most severe CDI cases.

Although C. difficile is implicated in most AAD cases, other causes of Non-C. difficile Pathogen-specific AAD should also be considered (Figure 3). C. perfringens type A has also been implicated in 3-20% cases.33,34 C. perfringens AAD is primarily mediated by enterotoxins (CPEnt) released by the organism. Borriello et al. first demonstrated 11 C. difficile negative AAD cases in whom enterotoxigenic C. perfringens was detected, that were not typical of C. perfringens food poisoning.35 Ten (91%) of the patients had reported taking antibiotics three weeks before the onset of diarrhea. All stool samples had high counts (>106 cfu/g) of C. perfringens and were CPEnt positive. Clinically, these patients had more severe and protracted symptoms compared to those of food poisoning. In addition, AAD due to C. perfringens does not result in the formation of pseudomembranes. The enterotoxin gene (cpe) in most C. perfringens-associated AAD cases is primarily plasmid-borne compared to chromosomal enterotoxic gene in food poisoning cases, potentially implying that C. perfringens-AAD may be a distinct entity by itself.36,37 Prevalence studies have reported wide differences in detecting C. perfringens enterotoxin vs C. difficile toxins.19 In one study, 693 stool samples with more than 90 percent of them showing clinical evidence of AAD were prospectively investigated to determine the frequencies of C. perfringens and C. difficile.38) Interestingly, while C. difficile toxin was detected in 79 (11.4%) cases and C. perfringens enterotoxin in only 1 (0.14%) case, C. perfringens was cultured almost twice as frequently as C. difficile in this study (21.2% vs 12%). On the other hand, studies have also reported similar frequencies in detecting CPEnt and C. difficile toxins.39 In some cases, CPEnt and C. difficile toxins were found to co-exist, suggesting that they may act in synergy to cause AAD. While it appears that C. perfringens is a cause of a subset of patients with AAD, further study of the etiologic agent is needed.

Figure 3. Pathogenesis of Non-C. difficile Pathogen-specific AAD.

Figure 3.

Open in a new tab

S. aureus induced AAD was identified early in the antibiotic era as a cause of AAD in hospitalized patients.40 Following the identification of C. difficile as an important cause of AAD and pseudomembranous colitis, S. aureus has largely been discounted as a potential etiologic agent in AAD. However, following the widespread emergence of MRSA, investigators in Japan and Australia have reported several cases of MRSA-associated AAD.41,42 Commonly identified risk factors of Staphylococcal enterocolitis included use of antibiotics (especially fluoroquinolones), advanced age, use of H2 blockers or proton pump inhibitors, HIV infection, immune suppressive therapy and recent partial or total gastrectomy.43–49 Although pathogenetic mechanisms in S. aureus AAD have not been well appreciated, S. aureus enterotoxins (A-E & TSST-1) have shown considerable experimental evidence to cause diarrhea.50 In France, investigators reported predominant MRSA growth in stools of some suspected AAD patients, most of which produced enterotoxin A and the bicomponent leucotoxin (LukE-LukD).45 Investigators have looked for clinical differences between S. aureus induced AAD vs. CDI. In one small study patients with S. aureus- associated AAD presented with greenish watery stools not seen in patients with CDI.51 A predominance of gram-positive cocci in clusters on gram stain in stool or on mucosal biopsy along with watery diarrhea supports the diagnosis. Froberg et al. reported a patient with simultaneous infections by C. difficile and S. aureus with two distinct pseudomembranous lesions.52 With S. aureus, the pseudomembranes were loosely adherent, yellowish-green and located primarily in the small bowel compared to tightly adherent, sharply demarcated, and small, eruptive pseudomembranes located in the cecum and the colon in CDI. Investigators also reported that clinical features of patients co-infected by both pathogens are likely to be more serious than those who are infected by single pathogen.53,54 Taken together, MRSA may have a valid role in the pathogenesis of AAD, particularly in cases of small bowel involvement and/or when predominantly present in the stool. Criteria however need to be established to initiate investigations.

K. oxytoca, a gram-negative facultative aerobic enterobacterium, has been shown to be the causative agent of antibiotic associated hemorrhagic colitis (AAHC).55 Although sharing some similarities with C. difficile, AAHC appears to be a clinically distinct form of colitis that is characterized by the absence of toxigenic C. difficile and the presence of hematochezia. It is predominantly segmental, involves the right colon and is associated typically with use of the penicillins since Klebsiella expresses beta-lactamases.55,56 Clinically, patients present with bloody diarrhea during antibiotic therapy, accompanied by severe abdominal cramps and often resolve spontaneously following cessation of antibiotics.55,57 The pathogenesis is related to the production of a cytotoxin that leads to epithelial cell death and predisposes patients to hemorrhagic colitis.57 Further evidence of the pathogenesis has been seen in studies where intraluminal administration of cytotoxin from the organism resulted in direct damage to the ileal mucosa that was demonstrated histologically.58 Colonoscopy typically reveals segmental distribution of mucosal inflammation and hemorrhage, predominantly in the right colon.55

Hogenauer et al. investigated patients who had suspected C. difficile negative AAD to determine the pathogenetic role of K. oxytoca in AAHC.55 Cultures for K. oxytoca were sent following a diagnosis of AAHC on diagnostic colonoscopy. Out of 22 consecutive C. difficile-negative AAD patients, six patients had findings consistent with hemorrhagic colitis on colonoscopy. Of those, five patients had positive stool cultures for K. oxytoca. K. oxytoca was also detected in the stools of 6 of the 385 healthy subjects, who had no gastrointestinal symptoms including diarrhea. Although the role of K. oxytoca was demonstrated in AAHC, it was not known if it played a similar role in nonhemorrhagic antibiotic associated colitis. Out of 371 stool samples in patients with suspected AAD, K. oxytoca was isolated in 15 samples, and C. difficile toxin in 14 of them. Among the K. oxytoca isolates, 6 were toxin producing, of which 3 were associated with only AAHC. There were no cases of nonhemorrhagic colitis detected.

The role of Candida spp. in AAD has been debated since the 1950s and continues to be controversial. Candida spp. normally colonizes the small and large intestine in insignificant numbers, and usually does not exceed 104 cfu/ml.59 However, they are also the most frequently encountered opportunistic fungal pathogen of the gastrointestinal tract following antibacterial therapy.60 In patients treated with antibiotics, increased fecal counts of Candida have been observed and have been tentatively linked to the development of diarrhea. However, this appears to be the consequence of antibiotic therapy rather than the cause.61 Some of the risk factors commonly associated with Candida infection besides antibacterial therapy (especially tetracyclines62) are increasing age, endocrine abnormalities, immune dysfunction, chemotherapy, neoplasm, and steroid therapy.62–65 Clinically these patients present with prolonged secretory diarrhea with abdominal pain and cramping but without blood, mucus, fever, nausea, or vomiting.

Several mechanisms have been suggested to explain why Candida spp. overgrowth may be associated with AAD. Reduction in the number of endogenous intestinal microbiota may result in proliferation of Candida spp. due to lack of growth restraints and presence of selective growth advantages. One study suggested that the interruption of the colonization resistance following exposure to tetracyclines could facilitate overgrowth of undesirable organisms such as C. albicans. This was supported by no growth of C. albicans when normal intestinal microbiota was present.62 Other studies that have shown supporting evidence have suggested that the diarrhea may be due to secretory changes in the gut,63,66 acquired lactase deficiency,67 abnormal lactose metabolism68 or inhibition of leukocyte activity following antibacterial therapy.63,66–69 In vitro and animal studies have shown that Candida spp. may alter gut immune mechanisms.70,71 However, there has been no convincing evidence that supports the role of soluble Candida inhibitors such as phospholipase in the pathogenesis of Candida associated AAD.72,73 In summary, the role of Candida spp. in AAD remains controversial although there may be an association between Candida overgrowth and AAD in selected patients such as elderly inpatients who are receiving antibiotics.73–75

Only 40% of AAD can be accounted for by the above causes leaving a majority of AAD cases without an etiology. Limited studies have shown that strains of Pseudomonas aeruginosa may be a possible cause of AAD.11,76–78 Song et al. provided some evidence that strains of K. pneumonia were associated with AAD and Vaishnavi et al. identified strains of Campyobacter jejuni in 14 out of 138 (10%) patients with AAD.11,79 Strains of Salmonella and C. jejuni have been associated with an increased rate of infection in people receiving antibiotics.80–83 However, pathogenic mechanisms of organisms such as Salmonella and C. jejuni have not been well described.

Nonmicrobial Causes of AAD

Non-microbial-causes of AAD tend to occur within 48-72 hours of starting antibiotics, tend to be less severe and usually are self-limiting. Macrolides such as erythromycin can cause stimulation of motilin receptors, increase gastric emptying, and decrease transit time. Beta-lactam antibiotics can cause osmotic diarrhea due to changes in degradation of non-absorbed carbohydrates, changes in bile salt degradation, and stimulation of c-AMP which increase bowel activity through increased chloride secretion. Amoxicillin/clavulanate also may cause increased nocturnal motility. Neomycin can cause steatorrhea, reduced vitamin B12 excretion, shortening of villi, infiltration of lamina propria with plasma cells, eosinophils and pigment containing macrophages. High dose clofazimine therapy may also cause red crystal deposition in the small bowel lamina propria and may result in severe and fatal enteropathy.84–89

DIAGNOSIS

It is essential to rule out other causes of AAD such as infection. For CDI, the diagnosis is commonly made by detection of Clostridioides difficile toxins by enzyme linked immunoassay (EIA) or using DNA based tests that identify the microbial toxin genes in unformed stool. Stool cultures may be sent to rule out other pathogens, if clinically indicated. Stool culture for Clostridioides difficile requires anerobic culture and is not widely available. Posttreatment testing has no role in confirming eradication of the infection. Endoscopy is indicated if patient has typical CDI presentation with negative Clostridioides difficile test results, there is no response to standard course of antibiotics, patient has overlapping inflammatory bowel disease or when an alternative diagnosis is suspected, and direct visualization and/or biopsy of the bowel mucosa is needed.90,91

TREATMENT

The first-line treatments for AAD are discontinuation of the offending antibiotic and supportive care including maintaining adequate hydration. For non-severe CDI, oral vancomycin 125mg four times daily for 10 days or fidaxomicin 200mg twice daily for 10 days is the first line treatment. If fidaxomicin or vancomycin are not available, metronidazole 500mg three times daily for 10 days can be alternatively used. If metronidazole is used and the patient does not show improvement or there is clinical worsening, a switch to vancomycin or fidaxomicin should be considered.92

For patients with severe CDI, oral vancomycin or fidaxomicin should be used as first line treatment. In fulminant cases of CDI, oral vancomycin 500mg four times daily and intravenous metronidazole 500mg every 8 hours are recommended. For patients with complete ileus or colonic diversion, addition of rectal vancomycin should be considered. Early surgical consultation for patients with fulminant CDI should also be considered. CDI recurrence (rCDI) is defined as recurrence of symptoms and positive C. difficle test within eight weeks of completing therapy. In patients with first rCDI, patients should be treated with fidaxomicin for 10 days or prolonged vancomycin taper if vancomycin was used initially. Oral vancomycin 125mg four times daily for 10 days may be used if metronidazole was used initially. In case of second or subsequent recurrences, patients may be treated with prolonged vancomycin taper or oral vancomycin followed by rifaximin course.93

Fecal microbial therapy (FMT) should be considered in patients with two or more recurrences to correct the disruption in microbiota caused by recurrent use of antibiotics. In a systematic review conducted by Quraishi et al. in 2017, clinical resolution occurred in 92% of the patients treated with FMT.94 In another study from the Netherlands, 81% of the patients had resolution of rCDI after a single duodenal FMT infusion compared to 31% in the vancomycin group.95 Limited RCT data also exists for monoclonal antibody treatments such as bezlotoxmumab (monoclonal antibody that binds to C.difficile toxin B) where patients were noted to have lower rates of rCDI than patients treated with antibiotics alone. There are ongoing trials for use of enema based microbial replacement, capsule-based therapies and FMT using nasogastric tube in pediatric patients.96,97 Probiotic use has shown conflicting results and more research is needed.98–100

CONCLUSION

As the prevalence of AAD increases, the health and economic burden associated with this illness continues to be significant. For better treatment options to be developed and the trend of increasing prevalence to be reversed, significant gains must be made in our understanding of the etiology and pathophysiology of AAD. The unique features of the current review were to summarize the existing data on AAD and provide concise descriptions of the pathogenesis of CDI as well as non-CDI AAD. Because a majority of the AAD cases are due to altered intestinal microbiota, modulating the microbiota, and adopting preventive strategies such as diet, prebiotics, probiotics, and drugs may be ultimately necessary to ensure optimal health and favorable outcomes in disease prone individuals. Future research must be directed towards identifying and better understanding some of the mechanisms that operate behind benign causes as well as other microbial causes of AAD. Efforts must also be made towards establishing criteria to identify at risk patients and to initiate investigations in these patients to ensure optimal utilization of resources and to reduce the economic impact.

Author Contribution

All Authors (VS, MAA) have reviewed the final manuscript prior to submission. All the authors have contributed significantly to the manuscript, per the ICJME criteria of authorship.

  • Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND

  • Drafting the work or revising it critically for important intellectual content; AND

  • Final approval of the version to be published; AND

  • Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Disclosures/Conflicts of Interest

The authors have no conflicts of interest to disclose.

Corresponding Author

Vijairam Selvaraj MD, MPH

164 Summit Ave

Department of Medicine

The Miriam Hospital and Warren Alpert Medical School of Brown University

Providence, RI 02906

Email: vijairam.selvaraj@lifespan.org

Ph: 401-793-2500

Fax: 401-793-4047

ORCID: 0000-0002-8507-9891

Funding Statement

No funding was obtained for this manuscript.

References

  1. Clinical prediction rules to optimize cytotoxin testing for Clostridium difficile in hospitalized patients with diarrhea. Katz David A., Lynch Mary E., Littenberg Benjamin. May;1996 The American Journal of Medicine. 100(5):487–495. doi: 10.1016/s0002-9343(95)00016-x. https://doi.org/10.1016/s0002-9343(95)00016-x [DOI] [PubMed] [Google Scholar]
  2. Mechanisms and management of antibiotic-associated diarrhea. Hogenauer Christoph, Hammer Heinz F., Krejs Guenter J., Reisinger Emil C. Oct;1998 Clinical Infectious Diseases. 27(4):702–710. doi: 10.1086/514958. https://doi.org/10.1086/514958 [DOI] [PubMed] [Google Scholar]
  3. Antibiotic-associated diarrhea: epidemiology, trends and treatment. McFarland Lynne V. Oct;2008 Future Microbiology. 3(5):563–578. doi: 10.2217/17460913.3.5.563. https://doi.org/10.2217/17460913.3.5.563 [DOI] [PubMed] [Google Scholar]
  4. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Kyne Lorraine, Warny Michel, Qamar Amir, Kelly Ciarán P. Jan;2001 The Lancet. 357(9251):189–193. doi: 10.1016/s0140-6736(00)03592-3. https://doi.org/10.1016/s0140-6736(00)03592-3 [DOI] [PubMed] [Google Scholar]
  5. Clinical manifestations and outcome of Pseudomembranous colitis in an elderly population in Israel. Moshkowitz M., Ben Baruch E., Kline Z., Moshe G., Shimoni Z., Konikoff F. 2004Isr Med Assoc J. 6:201–4. [PubMed] [Google Scholar]
  6. The treatment of severe staphylococcal infections with vancomycin. Woodley DONALD W., Hall W.H. Aug 1;1961 Annals of Internal Medicine. 55(2):235. doi: 10.7326/0003-4819-55-2-235. https://doi.org/10.7326/0003-4819-55-2-235 [DOI] [PubMed] [Google Scholar]
  7. Clindamycin-associated colitis. A prospective study. Tedesco FRANCIS J., Barton R.W., Alpers D.H. Oct 1;1974 Annals of Internal Medicine. 81(4):429. doi: 10.7326/0003-4819-81-4-429. https://doi.org/10.7326/0003-4819-81-4-429 [DOI] [PubMed] [Google Scholar]
  8. Tedesco Francis J., Stanley Robert J., Alpers David H. New England Journal of Medicine. 15. Vol. 290. Massachusetts Medical Society; Diagnostic features of clindamycin-associated pseudomembranous colitis; pp. 841–843.https://doi.org/10.1056/nejm197404112901508 [DOI] [PubMed] [Google Scholar]
  9. Guh Alice Y., Mu Yi, Winston Lisa G., Johnston Helen, Olson Danyel, Farley Monica M., Wilson Lucy E., Holzbauer Stacy M., Phipps Erin C., Dumyati Ghinwa K., Beldavs Zintars G., Kainer Marion A., Karlsson Maria, Gerding Dale N., McDonald L. Clifford. New England Journal of Medicine. 14. Vol. 382. Massachusetts Medical Society; Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes; pp. 1320–1330.https://doi.org/10.1056/nejmoa1910215 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Antibiotic-associated diarrhoea: an overlooked aetiology? Loy C.E. Jan;2005 British Journal of Biomedical Science. 62(4):166–169. doi: 10.1080/09674845.2005.11732705. https://doi.org/10.1080/09674845.2005.11732705 [DOI] [PubMed] [Google Scholar]
  11. Antibiotic-associated diarrhea: candidate organisms other than Clostridium difficile. Song Hyun Joo, Shim Ki-Nam, Jung Sung-Ae, Choi Hee Jung, Lee Mi Ae, Ryu Kum Hei, Kim Seong-Eun, Yoo Kwon. 2008The Korean Journal of Internal Medicine. 23(1):9. doi: 10.3904/kjim.2008.23.1.9. https://doi.org/10.3904/kjim.2008.23.1.9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Dupont Andrew W., Dupont Herbert L. Nature Reviews Gastroenterology & Hepatology. 9. Vol. 8. Springer Science and Business Media LLC; The intestinal microbiota and chronic disorders of the gut; pp. 523–531.https://doi.org/10.1038/nrgastro.2011.133 [DOI] [PubMed] [Google Scholar]
  13. Normal flora: diversity and functions. McFarland Lynne V. Jan;2000 Microbial Ecology in Health and Disease. 12(4):193–207. doi: 10.1080/08910600050216183. https://doi.org/10.1080/08910600050216183 [DOI] [Google Scholar]
  14. Hammer H F, Fine K D, Santa Ana C A, Porter J L, Schiller L R, Fordtran J S. Journal of Clinical Investigation. 6. Vol. 86. American Society for Clinical Investigation; Carbohydrate malabsorption. Its measurement and its contribution to diarrhea. pp. 1936–1944.https://doi.org/10.1172/jci114927 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Edwards C A, Duerden B I, Read N W. Gut. 4. Vol. 27. BMJ; Effect of clindamycin on the ability of a continuous culture of colonic bacteria to ferment carbohydrate. pp. 411–417.https://doi.org/10.1136/gut.27.4.411 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Roediger W E. Gut. 9. Vol. 21. BMJ; Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. pp. 793–798.https://doi.org/10.1136/gut.21.9.793 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Koning Catherina JM, Jonkers Daisy MAE, Stobberingh Ellen E, Mulder Linda, Rombouts Frans M, Stockbrügger Reinhold W. The American Journal of Gastroenterology. 1. Vol. 103. Ovid Technologies (Wolters Kluwer Health); The effect of a multispecies probiotic on the intestinal microbiota and bowel movements in healthy volunteers taking the antibiotic amoxycillin; pp. 178–189.https://doi.org/10.1111/j.1572-0241.2007.01547.x [DOI] [PubMed] [Google Scholar]
  18. Bile acids: short and long term effects in the intestine. Bajor Antal, Gillberg Per-Göran, Abrahamsson Hasse. Mar 24;2010 Scandinavian Journal of Gastroenterology. 45(6):645–664. doi: 10.3109/00365521003702734. https://doi.org/10.3109/00365521003702734 [DOI] [PubMed] [Google Scholar]
  19. Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus. Asha N. J., Tompkins D., Wilcox M. H. Aug;2006 Journal of Clinical Microbiology. 44(8):2785–2791. doi: 10.1128/jcm.00165-06. https://doi.org/10.1128/jcm.00165-06 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kinetic evidence for the presence of putative germination receptors in Clostridioides difficile spores. Ramirez Norma, Liggins Marc, Abel-Santos Ernesto. Aug 15;2010 Journal of Bacteriology. 192(16):4215–4222. doi: 10.1128/jb.00488-10. https://doi.org/10.1128/jb.00488-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Cwp84, a surface-associated protein of Clostridium difficile, is a cysteine protease with degrading activity on extracellular matrix proteins. Janoir Claire, Péchiné Séverine, Grosdidier Charlotte, Collignon Anne. Oct 15;2007 Journal of Bacteriology. 189(20):7174–7180. doi: 10.1128/jb.00578-07. https://doi.org/10.1128/jb.00578-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Cwp84, a surface-associated cysteine protease, plays a role in the maturation of the surface layer of Clostridium difficile. Kirby Jonathan M., Ahern Helen, Roberts April K., Kumar Vivek, Freeman Zoe, Acharya K.Ravi, Shone Clifford C. Dec;2009 Journal of Biological Chemistry. 284(50):34666–34673. doi: 10.1074/jbc.m109.051177. https://doi.org/10.1074/jbc.m109.051177 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Role of FliC and FliD flagellar proteins of Clostridium difficile in adherence and gut colonization. Tasteyre Albert, Barc Marie-Claude, Collignon Anne, Boureau Helene, Karjalainen Tuomo. Dec;2001 Infection and Immunity. 69(12):7937–7940. doi: 10.1128/iai.69.12.7937-7940.2001. https://doi.org/10.1128/iai.69.12.7937-7940.2001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Characterization of a cell surface protein of Clostridium difficile with adhesive properties. Waligora Anne-Judith, Hennequin Claire, Mullany Peter, Bourlioux Pierre, Collignon Anne, Karjalainen Tuomo. Apr;2001 Infection and Immunity. 69(4):2144–2153. doi: 10.1128/iai.69.4.2144-2153.2001. https://doi.org/10.1128/iai.69.4.2144-2153.2001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Hennequin Claire, Janoir Claire, Barc Marie-Claude, Collignon Anne, Karjalainen Tuomo. Microbiology. 10. Vol. 149. Microbiology Society; Identification and characterization of a fibronectin-binding protein from Clostridium difficile; pp. 2779–2787.https://doi.org/10.1099/mic.0.26145-0 [DOI] [PubMed] [Google Scholar]
  26. Manganese binds to Clostridium difficile Fbp68 and is essential for fibronectin binding. Lin Yi-Pin, Kuo Chih-Jung, Koleci Xhelil, McDonough Sean P., Chang Yung-Fu. Feb;2011 Journal of Biological Chemistry. 286(5):3957–3969. doi: 10.1074/jbc.m110.184523. https://doi.org/10.1074/jbc.m110.184523 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. GroEL (Hsp60) of Clostridium difficile is involved in cell adherence. Hennequin Claire, Porcheray Fabrice, Waligora-Dupriet Anne Judith, Karjalainen Tuomo, Barc Marie-Claude, Bourlioux Pierre, Collignon Anne. Jan 1;2001 Microbiology. 147(1):87–96. doi: 10.1099/00221287-147-1-87. https://doi.org/10.1099/00221287-147-1-87 [DOI] [PubMed] [Google Scholar]
  28. Calabi Emanuela, Ward Steven, Wren Brendan, Paxton Thanai, Panico Maria, Morris Howard, Dell Anne, Dougan Gordon, Fairweather Neil. Molecular Microbiology. 5. Vol. 40. Wiley; Molecular characterization of the surface layer proteins from Clostridium difficile; pp. 1187–1199.https://doi.org/10.1046/j.1365-2958.2001.02461.x [DOI] [PubMed] [Google Scholar]
  29. Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues. Calabi Emanuela, Calabi Franco, Phillips Alan D., Fairweather Neil F. Oct;2002 Infection and Immunity. 70(10):5770–5778. doi: 10.1128/iai.70.10.5770-5778.2002. https://doi.org/10.1128/iai.70.10.5770-5778.2002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. von Eichel-Streiber Christoph, Laufenberg-Feldmann Rita, Sartingen Sabine, Schulze Jörg, Sauerborn Markus. Molecular and General Genetics MGG. 1-2. Vol. 233. Springer Science and Business Media LLC; Comparative sequence analysis of theClostridium difficile toxins A and B; pp. 260–268.https://doi.org/10.1007/bf00587587 [DOI] [PubMed] [Google Scholar]
  31. Popoff M R, Rubin E J, Gill D M, Boquet P. Infection and Immunity. 9. Vol. 56. American Society for Microbiology; Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain; pp. 2299–2306.https://doi.org/10.1128/iai.56.9.2299-2306.1988 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Perelle S, Gibert M, Bourlioux P, Corthier G, Popoff M R. Infection and Immunity. 4. Vol. 65. American Society for Microbiology; Production of a complete binary toxin (actin-specific ADP-ribosyltransferase) by Clostridium difficile CD196; pp. 1402–1407.https://doi.org/10.1128/iai.65.4.1402-1407.1997 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Clostridium perfringens enterotoxin in antibiotic-associated diarrhea. Vaishnavi Chetana, Kaur Sukhminderjit. 2008Indian Journal of Pathology and Microbiology. 51(2):198. doi: 10.4103/0377-4929.41681. https://doi.org/10.4103/0377-4929.41681 [DOI] [PubMed] [Google Scholar]
  34. Incidence and characterization of Clostridium perfringens isolated from antibiotic-associated diarrhoeal patients: a prospective study in an Indian hospital. Joshy L., Chaudhry R., Dhawan B., Kumar L., Das B.K. Jul;2006 Journal of Hospital Infection. 63(3):323–329. doi: 10.1016/j.jhin.2005.12.015. https://doi.org/10.1016/j.jhin.2005.12.015 [DOI] [PubMed] [Google Scholar]
  35. Enterotoxigenic Clostridium perfringens: a possible cause of antibiotic-associated diarrhoea. Borriello S.P., Larson H.E., Welch A.R., Barclay Fiona, Stringer M.F., Bartholomew Barbara A. Feb;1984 The Lancet. 323(8372):305–307. doi: 10.1016/s0140-6736(84)90359-3. https://doi.org/10.1016/s0140-6736(84)90359-3 [DOI] [PubMed] [Google Scholar]
  36. Genotyping of enterotoxigenic Clostridium perfringens fecal isolates associated with antibiotic-associated diarrhea and food poisoning in North America. Sparks Shauna G., Carman Robert J., Sarker Mahfuzur R., McClane Bruce A. Mar;2001 Journal of Clinical Microbiology. 39(3):883–888. doi: 10.1128/jcm.39.3.883-888.2001. https://doi.org/10.1128/jcm.39.3.883-888.2001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Evidence that the enterotoxin gene can be episomal in Clostridium perfringens isolates associated with non-food-borne human gastrointestinal diseases. Collie Renee E., McClane Bruce A. Jan;1998 Journal of Clinical Microbiology. 36(1):30–36. doi: 10.1128/jcm.36.1.30-36.1998. https://doi.org/10.1128/jcm.36.1.30-36.1998 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Prevalence of Clostridium difficile toxins A and B and Clostridium perfringens enterotoxin A in stool samples of patients with antibiotic-associated diarrhea. Heimesaat M. M., Granzow K., Leidinger H., Liesenfeld O. Oct;2005 Infection. 33(5-6):340–344. doi: 10.1007/s15010-005-5067-3. https://doi.org/10.1007/s15010-005-5067-3 [DOI] [PubMed] [Google Scholar]
  39. Similar frequency of detection of Clostridium perfringens enterotoxin and Clostridium difficile toxins in patients with antibiotic-associated diarrhea. Abrahao C., Carman R.J., Hahn H., Liesenfeld O. Sep;2001 European Journal of Clinical Microbiology and Infectious Diseases. 20(9):676–677. doi: 10.1007/s100960100571. https://doi.org/10.1007/s100960100571 [DOI] [PubMed] [Google Scholar]
  40. Altemeier WILLIAM A., Hummel ROBERT P., Hill EDWORD O. Annals of Surgery. 6. Vol. 157. Ovid Technologies (Wolters Kluwer Health); Staphylococcal enterocolitis following antibiotic therapy; pp. 847–858.https://doi.org/10.1097/00000658-196306000-00003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. McDonald Malcolm, Ward Peter, Harvey Ken. Medical Journal of Australia. 11. Vol. 1. Wiley; Antibiotic‐associated diarrhoea and methicillin‐resistantStaphylococcus aureus; pp. 462–464.https://doi.org/10.5694/j.1326-5377.1982.tb132416.x [DOI] [PubMed] [Google Scholar]
  42. Kodama Takashi, Santo Takahiro, Yokoyama Takashi, Takesue Yoshio, Hiyama Eiso, Imamura Yuji, Murakami Yoshiaki, Tsumura Hiroaki, Shinbara Kanae, Tatsumoto Naokuni, Matsuura Yuichirou. Surgery Today. 9. Vol. 27. Springer Science and Business Media LLC; Postoperative enteritis caused by methicillin-resistantStaphylococcus aureus; pp. 816–825.https://doi.org/10.1007/bf02385272 [DOI] [PubMed] [Google Scholar]
  43. Successful treatment of methicillin-resistant Staphylococcus aureus (MRSA) enterocolitis in a neutropenic patient following cytotoxic chemotherapy. Chubachi Akihiko, Hashimoto Keiko, Miura Akira B. Aug;1993 American Journal of Hematology. 43(4):327–327. doi: 10.1002/ajh.2830430426. https://doi.org/10.1002/ajh.2830430426 [DOI] [PubMed] [Google Scholar]
  44. Boyce John M., Havill Nancy L. The American Journal of Gastroenterology. 8. Vol. 100. Ovid Technologies (Wolters Kluwer Health); Nosocomial antibiotic-associated diarrhea associated with enterotoxin-producing strains of methicillin-resistant Staphylococcus aureus; pp. 1828–1834.https://doi.org/10.1111/j.1572-0241.2005.41510.x [DOI] [PubMed] [Google Scholar]
  45. Predominant Staphylococcus aureus isolated from antibiotic-associated diarrhea is clinically relevant and produces enterotoxin A and the bicomponent toxin LukE-lukD. Gravet Alain, Rondeau Murielle, Harf-Monteil Colette, Grunenberger Fabienne, Monteil Henri, Scheftel Jean-Michel, Prévost Gilles. Dec;1999 Journal of Clinical Microbiology. 37(12):4012–4019. doi: 10.1128/jcm.37.12.4012-4019.1999. https://doi.org/10.1128/jcm.37.12.4012-4019.1999 [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Methicillin-resistant Staphylococcus aureus as a cause of antibiotic-associated diarrhea. Rhee Kyu Y., Soave Rosemary, Maltz Charles. Mar;2004 Journal of Clinical Gastroenterology. 38(3):299–300. doi: 10.1097/00004836-200403000-00023. https://doi.org/10.1097/00004836-200403000-00023 [DOI] [PubMed] [Google Scholar]
  47. Clinical studies of enteritis caused by methicillin-resistant Staphylococcus aureus. Takeuchi Kunio, Tsuzuki Yasushi, Ando Tetsu., et al. Apr 1;2001 The European Journal of Surgery. 167(4):293–296. doi: 10.1080/110241501300091507. https://doi.org/10.1080/110241501300091507 [DOI] [PubMed] [Google Scholar]
  48. Toxic shock-like syndrome associated with staphylococcal enterocolitis in an HIV-infected man. Kotler D. P., Sandkovsky U., Schlievert P. M., Sordillo E. M. Jun 15;2007 Clinical Infectious Diseases. 44(12):e121–e123. doi: 10.1086/518286. https://doi.org/10.1086/518286 [DOI] [PubMed] [Google Scholar]
  49. Methicillin-resistant Staphylococcal enterocolitis. Schiller Bradford, Chiorazzi Nicholas, Farber Bruce F. Aug;1998 The American Journal of Medicine. 105(2):164–166. doi: 10.1016/s0002-9343(98)80056-9. https://doi.org/10.1016/s0002-9343(98)80056-9 [DOI] [PubMed] [Google Scholar]
  50. Nakamura Yoichi, Aramaki Yukihiko, Kakiuchi Terutaka. Journal of Surgical Research. 1. Vol. 96. Elsevier BV; A mouse model for postoperative fatal enteritis due to Staphylococcus infection; pp. 35–43.https://doi.org/10.1006/jsre.2000.6043 [DOI] [PubMed] [Google Scholar]
  51. Antibiotic-associated diarrhea due to methicillin-resistant Staphylococcus aureus. Lo Tze Shien, Borchardt Stephanie M. Apr;2009 Diagnostic Microbiology and Infectious Disease. 63(4):388–389. doi: 10.1016/j.diagmicrobio.2008.12.007. https://doi.org/10.1016/j.diagmicrobio.2008.12.007 [DOI] [PubMed] [Google Scholar]
  52. Staphylococcus aureus and Clostridium difficile cause distinct pseudomembranous intestinal diseases. Froberg M. K., Palavecino E., Dykoski R., Gerding D. N., Peterson L. R., Johnson S. Sep 1;2004 Clinical Infectious Diseases. 39(5):747–750. doi: 10.1086/423273. https://doi.org/10.1086/423273 [DOI] [PubMed] [Google Scholar]
  53. Clinical spectrum of antibiotic associated enterocolitis due to methicillin resistant Staphylococcus aureus. Inamatsu T., Ooshima H., Masuda Y.., et al. 1992Nihon Rinsho. 50:1087–92. [PubMed] [Google Scholar]
  54. Flemming K., Ackermann G. Infection. 5. Vol. 35. Springer Science and Business Media LLC; Prevalence of enterotoxin producing Staphylococcus aureus in stools of patients with nosocomial diarrhea; pp. 356–358.https://doi.org/10.1007/s15010-007-6268-8 [DOI] [PubMed] [Google Scholar]
  55. Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. Högenauer Christoph, Langner Cord, Beubler Eckhard, Lippe Irmgard T., Schicho Rudolf, Gorkiewicz Gregor, Krause Robert, Gerstgrasser Nikolas, Krejs Guenter J., Hinterleitner Thomas A. Dec 7;2006 New England Journal of Medicine. 355(23):2418–2426. doi: 10.1056/nejmoa054765. https://doi.org/10.1056/nejmoa054765 [DOI] [PubMed] [Google Scholar]
  56. Antibiotic-associated hemorrhagic colitis caused by cytotoxin-producing Klebsiella oxytoca. Hoffmann K. Martin, Deutschmann Andrea, Weitzer Christa, Joainig Martina, Zechner Ellen, Högenauer Christoph, Hauer Almuthe C. Apr 1;2010 Pediatrics. 125(4):e960–e963. doi: 10.1542/peds.2009-1751. https://doi.org/10.1542/peds.2009-1751 [DOI] [PubMed] [Google Scholar]
  57. Amoxicillin-associated hemorrhagic colitis in the presence of Klebsiella oxytoca. Philbrick Ann M, Ernst Michael E. Nov;2007 Pharmacotherapy. 27(11):1603–1607. doi: 10.1592/phco.27.11.1603. https://doi.org/10.1592/phco.27.11.1603 [DOI] [PubMed] [Google Scholar]
  58. Minami J, Katayama S, Matsushita O, Sakamoto H, Okabe A. Infection and Immunity. 1. Vol. 62. American Society for Microbiology; Enterotoxic activity of Klebsiella oxytoca cytotoxin in rabbit intestinal loops; pp. 172–177.https://doi.org/10.1128/iai.62.1.172-177.1994 [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Mycological aspects of gastrointestinal microflora. Bernhardt H., Knoke M. Jan;1997 Scandinavian Journal of Gastroenterology. 32(Supplement):102–106. doi: 10.1080/00365521.1997.11720731. https://doi.org/10.1080/00365521.1997.11720731 [DOI] [PubMed] [Google Scholar]
  60. Role of Candida in antibiotic-associated diarrhea. Krause Robert, Schwab Egon, Bachhiesl Daniela, Daxböck Florian, Wenisch Christoph, Krejs Günter J., Reisinger Emil C. Oct 15;2001 The Journal of Infectious Diseases. 184(8):1065–1069. doi: 10.1086/323550. https://doi.org/10.1086/323550 [DOI] [PubMed] [Google Scholar]
  61. Candida and antibiotic-associated diarrhoea. Krause R., Reisinger E.C. Jan;2005 Clinical Microbiology and Infection. 11(1):1–2. doi: 10.1111/j.1469-0691.2004.00978.x. https://doi.org/10.1111/j.1469-0691.2004.00978.x [DOI] [PubMed] [Google Scholar]
  62. In vitro studies on colonization resistance of the human gut microbiota to Candida albicans and the effects of tetracycline and Lactobacillus plantarum LPK. Payne S., Gibson G., Wynne A., Hudspith B., Brostoff J., Tuohy K. 20034:1–8. Curr Issues Intest Microbiol 2003;4:1-8. [PubMed] [Google Scholar]
  63. Gupta Tej P., Ehrinpreis Murray N. Gastroenterology. 3. Vol. 98. Elsevier BV; Candida-associated diarrhea in hospitalized patients; pp. 780–785.https://doi.org/10.1016/0016-5085(90)90303-i [DOI] [PubMed] [Google Scholar]
  64. Resistance of SCID mice to Candida albicans administered intravenously or colonizing the gut: role of polymorphonuclear leukocytes and macrophages. Jensen J., Warner T., Balish E. Apr 1;1993 Journal of Infectious Diseases. 167(4):912–919. doi: 10.1093/infdis/167.4.912. https://doi.org/10.1093/infdis/167.4.912 [DOI] [PubMed] [Google Scholar]
  65. Fungus infections associated with antibiotic and steroid therapy. Torack Richard M. Jun;1957 The American Journal of Medicine. 22(6):872–882. doi: 10.1016/0002-9343(57)90023-2. https://doi.org/10.1016/0002-9343(57)90023-2 [DOI] [PubMed] [Google Scholar]
  66. Candida-associated diarrhea: a syndrome in search of credibility. Levine J., Dykoski R. K., Janoff E. N. Oct 1;1995 Clinical Infectious Diseases. 21(4):881–886. doi: 10.1093/clinids/21.4.881. https://doi.org/10.1093/clinids/21.4.881 [DOI] [PubMed] [Google Scholar]
  67. Depression of lactase activity in the small intestine of infant rabbits by Candida albicans. Bishop R. F., Barnes G. L. May 1;1974 Journal of Medical Microbiology. 7(2):259–263. doi: 10.1099/00222615-7-2-259. https://doi.org/10.1099/00222615-7-2-259 [DOI] [PubMed] [Google Scholar]
  68. Effect of microorganisms isolated from the upper gut of malnourished children on intestinal sugar absorption in vivo. Gracey M, Burke V, Thomas J A, Stone D E. Aug 1;1975 American Journal of Clinical Nutrition. 28(8):841–845. doi: 10.1093/ajcn/28.8.841. https://doi.org/10.1093/ajcn/28.8.841 [DOI] [PubMed] [Google Scholar]
  69. Effect of tetracycline on the phagocytic function of human leukocytes. Forsgren A., Schmeling D., Quie P. G. Oct 1;1974 Journal of Infectious Diseases. 130(4):412–415. doi: 10.1093/infdis/130.4.412. https://doi.org/10.1093/infdis/130.4.412 [DOI] [PubMed] [Google Scholar]
  70. Dendritic cells discriminate between yeasts and hyphae of the fungus Candida albicans. Implications for initiation of T helper cell immunity in vitro and in vivo. d'Ostiani Cristiana Fè, Del Sero Giuseppe, Bacci Angela, Montagnoli Claudia, Spreca Antonio, Mencacci Antonella, Ricciardi-Castagnoli Paola, Romani Luigina. May 8;2000 Journal of Experimental Medicine. 191(10):1661–1674. doi: 10.1084/jem.191.10.1661. https://doi.org/10.1084/jem.191.10.1661 [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Rotstein Dalia, Parodo Jean, Taneja Ravi, Marshall John C. Shock. 3. Vol. 14. Ovid Technologies (Wolters Kluwer Health); Phagocytosis of Candida albicans induces apoptosis of human neutrophils; pp. 278–283.https://doi.org/10.1097/00024382-200014030-00006 [DOI] [PubMed] [Google Scholar]
  72. Elevated fecal Candida counts in patients with antibiotic-associated diarrhea: role of soluble fecal substances. Krause Robert, Krejs Günter J., Wenisch Christoph, Reisinger Emil C. Jan;2003 Clinical and Vaccine Immunology. 10(1):167–168. doi: 10.1128/cdli.10.1.167-168.2003. https://doi.org/10.1128/cdli.10.1.167-168.2003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Speciation of fecal Candida isolates in antibiotic-associated diarrhea in non-HIV patients. Vaishnavi C., Kaur S., Prakash S. 2008Jpn J Infect Dis. 61:1–4. [PubMed] [Google Scholar]
  74. Cholestyramine treatment of chronic diarrhea associated with immune deficiency syndrome. Bujanover Yoram, Sullivan Peter, Liebman William M., Goodman Joseph, Thaler M. Michael. Oct;1979 Clinical Pediatrics. 18(10):630–633. doi: 10.1177/000992287901801012. https://doi.org/10.1177/000992287901801012 [DOI] [PubMed] [Google Scholar]
  75. Role of candida in pathogenesis of antibiotic-associated diarrhoea in elderly inpatients. Danna P.L., Urban Carl, Bellin Eran, Rahal J.J. Mar;1991 The Lancet. 337(8740):511–514. doi: 10.1016/0140-6736(91)91296-7. https://doi.org/10.1016/0140-6736(91)91296-7 [DOI] [PubMed] [Google Scholar]
  76. Pseudomonas aeruginosa as a potential cause of antibiotic-associated diarrhea. Kim Shin Woo, Peck Kyong Ran, Jung Sook In, Kim Yeon Sook, Kim Sungmin, Lee Nam Yong, Song Jae Hoon. 2001Journal of Korean Medical Science. 16(6):742. doi: 10.3346/jkms.2001.16.6.742. https://doi.org/10.3346/jkms.2001.16.6.742 [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Porco Frank V, Visconte Ernest B. Annals of Pharmacotherapy. 11. Vol. 29. SAGE Publications; Pseudomonas aeruginosa as a cause of infectious diarrhea successfully treated with oral ciprofloxacin; pp. 1122–1123.https://doi.org/10.1177/106002809502901110 [DOI] [PubMed] [Google Scholar]
  78. Adlard P. A., Kirov S. M., Sanderson K., Cox G. E. Epidemiology and Infection. 1. Vol. 121. Cambridge University Press (CUP); Pseudomonas aeruginosa as a cause of infectious diarrhoea; pp. 237–241.https://doi.org/10.1017/s095026889800106x [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Is Campylobacter involved in antibiotic associated diarrhoea? Vaishnavi C., Kaur S. 2005Indian J Pathol Microbiol. 48:526–9. [PubMed] [Google Scholar]
  80. Sporadic Campylobacter jejuni infections in Hawaii: associations with prior antibiotic use and commercially prepared chicken. Effler Paul, Ieong Man‐Cheng, Kimura Akiko, Nakata Michele, Burr Roger, Cremer Erick, Slutsker Laurence. Apr;2001 The Journal of Infectious Diseases. 183(7):1152–1155. doi: 10.1086/319292. https://doi.org/10.1086/319292 [DOI] [PubMed] [Google Scholar]
  81. Characterisation of fluoroquinolone-resistant Campylobacter species isolated from human beings and chickens. Moore J. E., McLernon P., Xu J., Murphy P. G., Wareing D. Apr;2002 Veterinary Record. 150(16):518–520. doi: 10.1136/vr.150.16.518. https://doi.org/10.1136/vr.150.16.518 [DOI] [PubMed] [Google Scholar]
  82. Characterization of antimicrobial resistance of Salmonella Newport isolated from animals, the environment, and animal food products in Canada. Poppe C., Martin L., Muckle A., Archambault M., McEwen S., Weir E. 2006Can J Vet Res. 70:105–14. [PMC free article] [PubMed] [Google Scholar]
  83. Highly resistant Salmonella Newport-MDRAmpC transmitted through the domestic US food supply: a FoodNet case-control study of sporadic Salmonella Newport infections, 2002-2003. Varma Jay K., Marcus Ruthanne, Stenzel Sara A., Hanna Samir S., Gettner Sharmeen, Anderson Bridget J., Hayes Tameka, Shiferaw Beletshachew, Crume Tessa L., Joyce Kevin, Fullerton Kathleen E., Voetsch Andrew C., Angulo Frederick J. Jul 15;2006 The Journal of Infectious Diseases. 194(2):222–230. doi: 10.1086/505084. https://doi.org/10.1086/505084 [DOI] [PubMed] [Google Scholar]
  84. Caron F, Ducrotte P, Lerebours E, Colin R, Humbert G, Denis P. Antimicrobial Agents and Chemotherapy. 6. Vol. 35. American Society for Microbiology; Effects of amoxicillin-clavulanate combination on the motility of the small intestine in human beings; pp. 1085–1088.https://doi.org/10.1128/aac.35.6.1085 [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridum difficile-associated disease. Manges Amee R., Labbe Aurelie, Loo Vivian G., Atherton Juli K., Behr Marcel A., Masson Luke, Tellis Patricia A., Brousseau Roland. Dec 15;2010 The Journal of Infectious Diseases. 202(12):1877–1884. doi: 10.1086/657319. https://doi.org/10.1086/657319 [DOI] [PubMed] [Google Scholar]
  86. Catnach S M, Fairclough P D. Gut. 3. Vol. 33. BMJ; Erythromycin and the gut. pp. 397–401.https://doi.org/10.1136/gut.33.3.397 [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Clofazimine enteropathy in a pediatric bone marrow transplant recipient. Parizhskaya Maria, Youssef Nader N., Di Lorenzo Carlo, Goyal Rakesh K. Apr;2001 The Journal of Pediatrics. 138(4):574–576. doi: 10.1067/mpd.2001.111327. https://doi.org/10.1067/mpd.2001.111327 [DOI] [PubMed] [Google Scholar]
  88. Clofazimine enteropathy: possible relation to Peyer's patches. Levine S., Saltzman A. 1986Int J Lepr Other Mycobact Dis. 54:392–8. [PubMed] [Google Scholar]
  89. Morphologic alterations associated with neomycin induced malabsorption. Dobbins W. O., III, Herrero B. A., Mansbach C. M. Jan;1968 The American Journal of The Medical Sciences. 225(1):63–77. doi: 10.1097/00000441-196801000-00011. https://doi.org/10.1097/00000441-196801000-00011 [DOI] [PubMed] [Google Scholar]
  90. Clostridium difficile infection. Leffler Daniel A., Lamont J. Thomas. Apr 16;2015 New England Journal of Medicine. 372(16):1539–1548. doi: 10.1056/nejmra1403772. https://doi.org/10.1056/nejmra1403772 [DOI] [PubMed] [Google Scholar]
  91. Clostridium difficile infection: review. Czepiel Jacek, Dróżdż Mirosław, Pituch Hanna, Kuijper Ed J., Perucki William, Mielimonka Aleksandra, Goldman Sarah, Wultańska Dorota, Garlicki Aleksander, Biesiada Grażyna. Apr 3;2019 European Journal of Clinical Microbiology & Infectious Diseases. 38(7):1211–1221. doi: 10.1007/s10096-019-03539-6. https://doi.org/10.1007/s10096-019-03539-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) McDonald L Clifford, Gerding Dale N, Johnson Stuart, Bakken Johan S, Carroll Karen C, Coffin Susan E, Dubberke Erik R, Garey Kevin W, Gould Carolyn V, Kelly Ciaran, Loo Vivian, Shaklee Sammons Julia, Sandora Thomas J, Wilcox Mark H. Feb 15;2018 Clinical Infectious Diseases. 66(7):e1–e48. doi: 10.1093/cid/cix1085. https://doi.org/10.1093/cid/cix1085 [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Update on Treatment of Clostridioides difficile Infection. Cho Janice M., Pardi Darrell S., Khanna Sahil. Apr;2020 Mayo Clinic Proceedings. 95(4):758–769. doi: 10.1016/j.mayocp.2019.08.006. https://doi.org/10.1016/j.mayocp.2019.08.006 [DOI] [PubMed] [Google Scholar]
  94. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractoryClostridium difficileinfection. Quraishi M. N., Widlak M., Bhala N., Moore D., Price M., Sharma N., Iqbal T. H. Jul 14;2017 Alimentary Pharmacology & Therapeutics. 46(5):479–493. doi: 10.1111/apt.14201. https://doi.org/10.1111/apt.14201 [DOI] [PubMed] [Google Scholar]
  95. Duodenal infusion of donor feces for recurrent Clostridium difficile. van Nood Els, Vrieze Anne, Nieuwdorp Max, Fuentes Susana, Zoetendal Erwin G., de Vos Willem M., Visser Caroline E., Kuijper Ed J., Bartelsman Joep F.W.M., Tijssen Jan G.P., Speelman Peter, Dijkgraaf Marcel G.W., Keller Josbert J. Jan 31;2013 New England Journal of Medicine. 368(5):407–415. doi: 10.1056/nejmoa1205037. https://doi.org/10.1056/nejmoa1205037 [DOI] [PubMed] [Google Scholar]
  96. Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection. Dubberke Erik R, Lee Christine H, Orenstein Robert, Khanna Sahil, Hecht Gail, Gerding Dale N. Mar 29;2018 Clinical Infectious Diseases. 67(8):1198–1204. doi: 10.1093/cid/ciy259. https://doi.org/10.1093/cid/ciy259 [DOI] [PubMed] [Google Scholar]
  97. Fecal microbiota transplantation via nasogastric tube for recurrent clostridium difficile infection in pediatric patients. Kronman Matthew P., Nielson Heather J., Adler Amanda L., Giefer Matthew J., Wahbeh Ghassan, Singh Namita, Zerr Danielle M., Suskind David L. Jan;2015 Journal of Pediatric Gastroenterology & Nutrition. 60(1):23–26. doi: 10.1097/mpg.0000000000000545. https://doi.org/10.1097/mpg.0000000000000545 [DOI] [PubMed] [Google Scholar]
  98. McFarland Lynne V. The American Journal of Gastroenterology. 4. Vol. 101. Ovid Technologies (Wolters Kluwer Health); Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease; pp. 812–822.https://doi.org/10.1111/j.1572-0241.2006.00465.x [DOI] [PubMed] [Google Scholar]
  99. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Pillai Anjana, Nelson Richard L. Jan 23;2008 Cochrane Database of Systematic Reviews. (1):CD004611. doi: 10.1002/14651858.cd004611.pub2. https://doi.org/10.1002/14651858.cd004611.pub2 [DOI] [PMC free article] [PubMed]
  100. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Lau Christine S., Chamberlain Ronald S. Feb;2016 International Journal of General Medicine. 9:27–37. doi: 10.2147/ijgm.s98280. https://doi.org/10.2147/ijgm.s98280 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Brown Journal of Hospital Medicine are provided here courtesy of Department of Medicine of Alpert Medical School of Brown University

RESOURCES